1-2 of 2
Katja Gutmair
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Christian Buske, Efstathios Kastritis, Alexander Grunenberg, Andreas Viardot, Dajana Kaczynski, Heike Mund, Katja Gutmair, Matthias Zingerle, Paul Duewel, Susanne Saussele, Björn Schöttker, Ullrich Graeven, Martin Dreyling, Andrea Kerkhoff, Thomas Weber, Holger F. Hebart, Ralf Ulrich Trappe, Lisa Kaiser, Elke Runge, Jasmin Mark, Simone Ferrero, Daniela Drandi, Falko Fend, Irina Bonzheim, Eva Hoster, Jens Dreyhaupt, Meletios A. Dimopoulos
Journal: Blood
Blood (2024) 144 (Supplement 1): 859.
https://doi.org/10.1182/blood-2024-200604
Published: 2024
Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Marco Ladetto, Katja Gutmair, Jeanette K Doorduijn, Eva Gine, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trneny, Vibeke KJ Vergote, Piero Maria Stefani, Netanel A. Horowitz, Maria Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Christiane Pott, Wolfram Klapper, Christian Schmidt, Michael Unterhalt, Martin Dreyling, Eva Hoster
Journal: Blood
Blood (2024) 144 (Supplement 1): 237.
https://doi.org/10.1182/blood-2024-201441
Published: 2024